Cansino (688185.SH): 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxoid) approved for clinical trial

Zhitong Finance App News, Cansino (688185.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for the 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/tetanus toxin) (“PCV24”) approved and issued by the State Drug Administration, agreeing to carry out clinical trials to prevent infectious diseases caused by the 24 pneumococcal serotypes contained in this product.

The company's PCV24 covers the main popular serotypes of pneumococci at present. It uses a covalent combination of polysaccharide antigen with protein carriers and dual carrier technology. It is intended to be suitable for vaccination of people aged 2 months (minimum 6 weeks) to prevent infectious diseases caused by 24 pneumococcal serotypes. The product completed the development and confirmation of 24 serotype purified polysaccharides, polysaccharide protein conjugate stock solution production processes, and finished product prescriptions. As of the date of disclosure of the announcement, the 24-valent pneumococcal polysaccharide conjugate vaccine had no marketed products at home or abroad.